[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628741":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":34,"locations":33,"responsibleParty":40,"collaborators":33,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":33,"enrollmentInfo":54,"targetDuration":33,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":77,"whyStopped":33,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":33},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Contingency Management Intervention","EXPERIMENTAL","Participants receive a PEth based contingency management intervention designed to promote alcohol abstinence. Participants undergo serial phosphatidylethanol (PEth) testing using dried blood spot samples. Financial incentives are provided contingent on alcohol abstinence or significant reduction in alcohol use as measured by PEth levels. The intervention lasts 12 weeks with follow up through 24 weeks.",[13],"Behavioral: PEth Based Contingency Management",{"label":15,"type":16,"description":17,"interventionNames":18},"PEth Monitoring Control","ACTIVE_COMPARATOR","Participants undergo the same schedule of PEth testing using dried blood spot samples but receive fixed incentives that are not contingent on alcohol use outcomes. This arm controls for monitoring and compensation while isolating the behavioral effect of contingency management.",[19],"Behavioral: PEth Monitoring with Fixed Incentives",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BEHAVIORAL","PEth Based Contingency Management","Participants receive a contingency management intervention designed to promote alcohol abstinence among patients with alcohol use disorder and alcohol associated liver disease. Alcohol use is monitored using serial phosphatidylethanol (PEth) testing from dried blood spot samples. Participants receive financial incentives contingent on alcohol abstinence or substantial reduction in alcohol consumption as measured by PEth levels. Incentives escalate with consecutive negative PEth results during the 12 week intervention period.",[9],[27],"Contingency Management for Alcohol Abstinence",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"PEth Monitoring with Fixed Incentives","Participants undergo serial phosphatidylethanol (PEth) testing using dried blood spot samples at the same schedule as the intervention group. Participants receive fixed incentives for completing testing visits, but incentives are not contingent on alcohol use outcomes. This condition controls for study participation, monitoring, and compensation while isolating the effect of contingency management.",[15],[15],null,[35],{"name":36,"role":37,"phone":38,"phoneExt":33,"email":39},"Wei Zhang, MD PHD","CONTACT","16177265925","wzhang50@mgh.harvard.edu",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"PRINCIPAL_INVESTIGATOR","Wei Zhang","Assistant Professor of Medicine, Harvard Medical School","100628741","financial-rewards-for-reducing-alcohol-use-in-patients-with-liver-disease-100628741",false,"NCT07465588","Financial Rewards for Reducing Alcohol Use in Patients With Liver Disease","Randomized Evaluation of Incentives FOR Clinical Effectiveness in Liver Recovery (REINFORCE Trial): A PEth-Based Contingency Management Pilot Randomized Controlled Trial for Alcohol Use Disorder in Patients With Alcohol-Associated Liver Disease","REINFORCE","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of alcohol use disorder based on DSM 5 criteria\n* Diagnosis of alcohol associated liver disease or clinically suspected alcohol related liver injury\n* Evidence of recent alcohol use or at risk for alcohol relapse\n* Receiving care in hepatology or liver disease clinic at the participating institution\n* Willingness to undergo serial phosphatidylethanol (PEth) testing using dried blood spot samples\n* Ability to provide informed consent\n* Willingness to participate in the contingency management intervention and follow study procedures\n\nExclusion Criteria:\n\n* Severe cognitive impairment or medical condition that prevents participation in study procedures\n* Active psychosis or severe psychiatric instability that would interfere with participation\n* Current enrollment in another contingency management program targeting alcohol use\n* Medical instability requiring hospitalization at the time of enrollment\n* Inability to communicate in English (if study materials are only available in English)\n* Any condition that, in the opinion of the investigators, would make participation unsafe or interfere with completion of the study","ALL","18 Years",{"count":55,"type":56},90,"ESTIMATED","INTERVENTIONAL",[59],"NA","This study tests whether providing financial rewards based on a blood test result can help people with alcohol-associated liver disease (ALD) stop or reduce their drinking. The blood test is called phosphatidylethanol (PEth), which can detect alcohol use over the past three to four weeks. The financial reward program is called contingency management (CM).\n\nThe study has two parts. Part 1 involves one-time interviews and surveys with patients and healthcare providers to understand how a PEth-based CM program could best be delivered in a liver disease clinic. Part 2 is a pilot randomized controlled trial (the REINFORCE Trial) in which participants are randomly assigned to one of two groups: (1) a rewards group that receives escalating financial incentives when PEth results show reduced or no alcohol use, or (2) a monitoring group that receives fixed payments regardless of PEth results. Both groups receive PEth testing and continue their usual medical care. The study will assess whether the rewards program improves alcohol abstinence and reduction at 12 and 24 weeks.'",[62,63,64,65],"Alcohol Use Disorder","Alcohol-associated Liver Disease","Liver Cirrhosis, Alcoholic","Alcohol-Associated Hepatitis",[67,68,69,70,71,72,73,74,75,76],"Contingency Management","Phosphatidylethanol","PEth","Dried Blood Spot","Alcohol Biomarker","Alcohol Abstinence","Hepatology","Liver Disease","Financial Incentives","Behavioral Intervention","NOT_YET_RECRUITING","2026-03-10",{"date":80,"type":81},"2026-03-12","ACTUAL",{"date":83,"type":56},"2026-08-01",{"date":85,"type":56},"2028-06-30",{"name":5,"class":6}]